The JAMA Network, February 18, 2013. A study in JAMA shows that women have a higher risk of implant failure than men following total hip replacement. In a commentary, NRC President Diana Zuckerman stresses that long-term comparative effectiveness data would enable patients and their physicians to choose the hip devices and surgical techniques that are most likely to be successful for a longer period.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Antibiotics: When Science and Wishful Thinking Collide
Health Affairs Blog, January 25, 2013. Antibiotic resistance is a major concern confronting our health care system, and there is tremendous pressure on the Food and Drug Administration (FDA) to “do something” about it. Unfortunately, the FDA is responding by approving drugs that are likely to do more harm than good.
Read More »Metal Hip Implants Face Tighter Controls
Wall Street Journal, January 18, 2013. Diana Zuckerman, president of the National Research Center for Women & Families, said: “There are so many shortcuts at the FDA device center that they often take a shortcut and approve a product with minimal safety testing.”
Read More »Interview With Dr. Diana Zuckerman on the Dangers of Anti-psychotic Drug Overuse in Nursing Homes
Healthcare Policy Podcast, December 21, 2012. During this 30 minute interview, Dr. Zuckerman discusses the long-standing and widespread overuse or misuse of anti-psychotics in medicating nursing home residents.
Read More »J&J Bedaquline and the Evolving Role for Accelerated Approval: Confirming Safety, Not Efficacy?
FDA Beat, December 4, 2012. Discussions during an advisory committee review Janssen’s TB drug bedaquiline showed some interesting thinking around accelerated approval and how much uncertainty can be acceptable—especially when it comes to safety. Yttri warned called “approval of drugs based on the promise of benefit” a “dangerous practice.”
Read More »